About the possibility of using a new biologically active supplement in the treatment of chronic venous diseases

Introduction. The use of various venotonic drugs is an integral part of the comprehensive treatment of patients with chronic venous diseases (CVD).

Aim. To evaluate the clinical efficacy of a new domestic biologically active supplement (BAS) consisting of the flavonoid hesperidin methyl chalcone (HMC), troxerutin (HER) and ascorbic acid (VitC) in the complex treatment of patients with CVD of clinical classes C1–C3 (according to CEAP).

Materials and methods. The open, comparative multicenter, prospective study included 281 patients with CVD (varicose veins) of clinical classes C1–C3 (according to CEAR). The first (studied) group of patients included 158 people who received Russian biologically active supplement (HMC + HER + VitC) for two months. The second (control) group consisted of 123 patients who did not receive biologically active supplement. In order to study the effectiveness of BAS sequentially during three patient visits, a statistical analysis of changes in quality of life according to the CIVIQ-2 questionnaire, pain intensity using a visual analog scale (VAS) and the dynamics of changes in malleolar volume (MV) on the target limb under study was performed.

Results. The results of the conducted studies have shown that the inclusion of a new Russian biologically active supplement (HMC + HER +VitC) in the complex treatment of patients with CVD significantly reduces symptoms and improves the quality of life of patients. The maximum effectiveness of Russian biologically active supplement (HMC + HER + VitC) is manifested after 2 months of use in standard dosages without any side effects. The main advantage of the new biologically active supplement is its complete solubility in water and, as a result, higher bioavailability.

Conclusions. The results of the conducted studies have shown that the inclusion of a new Russian biologically active supplement supplement (HMC + HER + VitC) in the complex treatment of patients with CVD significantly reduces symptoms and improves the quality oflife of patients.

1. Bogachev VYu, Rodionov SV, Dzhenina DM. Pharmacotherapy of chronic vein diseases. New European guidelines. Ambulatornaya Khirurgiya. 2018;(3-4):12–21. (In Russ.) https://doi.org/10.21518/1995-1477-2018-3-4-12-21.

2. Martinez-Zapata MJ, Vernooij RWM, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020;11(11):CD003229. https://doi.org/10.1002/14651858.CD003229.pub4.

3. Petrikov AS. Diosmin and Hespiridin: Are All Effects Known? Lechebnoe Delo. 2023;(1):12–28. (In Russ.) https://doi.org/10.24412/2071-5315-2023-12949.

4. Stepanova EF, Remezova IP, Shevchenko AM, Morozov AV, Maltseva VK. Phleboprotectors based on flavonoids: dosage forms, biopharmaceutical characteristics, technological features. Farmatsiya i Farmakologiya. 2020;8(6):405–415. https://doi.org/10.19163/2307-9266-2020-8-6-405-415.

5. Nicolaides AN. The Benefits of Micronized Purified Flavonoid Fraction (MPFF) Throughout the Progression of Chronic Venous Disease. Adv Ther. 2020;37(Suppl. 1):1–5. https://doi.org/10.1007/s12325-019-01218-8.

6. Savelyeva MI, Sychev DA. Possibilities of pharmacokinetic modelling of venotonics illustrated by an example of flavonoids. Angiology and Vascular Surgery. 2018;24(4):76–80. (In Russ.) Available at: https://angiologia.ru/journals/angiolsurgery/2018/4/10.php.

7. Kurginyan HM, Raskin VV. Modern view on the therapy of chronic venous insufficiency with micronized purified flavonoid fraction. Cardiovascular Therapy and Prevention (Russian Federation). 2020;19(4):2592. (In Russ.) https://doi.org/10.15829/1728-8800-2020-2592.

8. Cao R, Zhao Y, Zhou Z, Zhao X. Enhancement of the water solubility and antioxidant activity of hesperidin by chitooligosaccharide. J Sci Food Agric. 2018;98(6):2422–2427. https://doi.org/10.1002/jsfa.8734.

9. Guilding C, White PJ, Cunningham M, Kelly-Laubscher R, Koenig J, Babey AM et al. Defining and unpacking the core concepts of pharmacology A global initiative. Br J Pharmac. 2024;181(3):375–392. https://doi.org/10.1111/bph.16222.

10. Mazumder R, Ichudaule, Ghosh A, Deb S, Ghosh R. Significance of Chalcone Scaffolds in Medicinal Chemistry. Top Curr Chem. 2024;382(3):22. https://doi.org/10.1007/s41061-024-00468-7.

11. Pinho-Ribeiro FA, Hohmann MS, Borghi SM, Zarpelon AC, Guazelli CF, Manchope MF et al. Protective effects of the flavonoid hesperidin methyl chalcone in inflammation and pain in mice: role of TRPV1, oxidative stress, cytokines and NF- B. Chem Biol Interact. 2015;228:88–99. https://doi.org/10.1016/j.cbi.2015.01.011.

12. Guazelli CFS, Fattori V, Ferraz CR, Borghi SM, Casagrande R, Baracat MM, Verri WA. Antioxidant and anti-inflammatory effects of hesperidin methyl chalcone in experimental ulcerative colitis. Chem Biol Interact. 2021;333:109315. https://doi.org/10.1016/j.cbi.2020.109315.

13. Luque MZ, Aguiar AF, da Silva-Araújo AK, Zaninelli TH, Heintz OK, Saraiva-Santos T et al. Evaluation of a preemptive intervention regimen with hesperidin methyl chalcone in delayed-onset muscle soreness in young adults: a randomized, double-blinded, and placebocontrolled trial study. Eur J Appl Physiol. 2023;123(9):1949–1964. https://doi.org/10.1007/s00421-023-05207-2.

14. Borghi SM, Casagrande R, Verri WA. Hesperidin Methyl Chalcone: An Emerging Compound for the Treatment of Inflammation and Pain. Curr Med Chem. 2023;30(5):601–603. https://doi.org/10.2174/0929867329666220822113459.

15. De Maeseneer MD, Kakkos SK, Aherne T, Baekgaard N, Black S, Blomgren L et al. Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. 2022. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. https://doi.org/10.1016/j.ejvs.2021.12.024.

16. Gloviczki P, Dalsing MC, Gloviczki ML, Lurie F, Moneta GL, Shortell C, Wakefield TW. Handbook of Venous and Lymphatic Disorders. Guidelines of the American Venous Forum. CRC Press: Taylor & Francis Group; 2024. 894 p. https://doi.org/10.1201/9781003328971.

17. Russian clinical guidelines for the diagnosis and treatment of chronic venous diseases. Flebologiya. 2018;12(3):146–240. (In Russ.) https://doi.org/10.17116/flebo201870311-46.

18. Апханова ТВ, Булатов ВЛ, Вахратьян ПЕ, Волков АМ, Волков АС, Гаврилова ЕК и др. Клинические рекомендации Варикозное расширение вен. Ассоциация флебологов России, 2024. Режим доступа: https://phlebounion.ru/files/uploads/rek-afr/АФР%20КР%20 ВРВ%202024.pdf.

19. Martinez MJ, Bonfill X, Moreno RM, Vargas E, Capella D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2005;(3):CD003229. https://doi.org/10.1002/14651858.CD003229.pub2.

20. Garner RC, Garner JV, Gregory S, Whattam M, Calam A, Leong D. Comparison of the absorption of micronized (Daflon 500 mg) and nonmicronized 14C-diosmin tablets after oral administration to healthy volunteers by accelerator mass spectrometry andliquid scintillation counting. J Pharm Sci. 2002;91(1):32–40. https://doi.org/10.1002/jps.1168.